Clinical trial Recruiting at 1 site Interventional Ages 18 to 65 Women only

Scapulothoracic Stabilization and Postural Training Added to Lymphedema Care for Upper Arm Lymphedema After Breast Cancer

Official title: Effects of Scapulothoracic Stabilization and Postural Training Added to Standard Lymphedema Care on Muscle Strength, Posture and Functional Outcomes in Secondary Upper Extremity Lymphedema: A Single-Center Randomized Controlled Trial

Run by Toros University · NCT07697495 · Data updated 2026-11-12

This trial tests whether adding scapulothoracic stabilization and postural training to standard lymphedema care helps women with secondary upper-extremity lymphedema after breast cancer treatment.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexWomen only
Enrollment60 (estimated)
SponsorToros University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Adana)
StatusRecruiting
StartedMarch 1, 2026
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedJuly 13, 2026
Trial IDNCT07697495 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–65 with secondary upper-extremity lymphedema after breast cancer surgery (mastectomy).

Probably not a fit

Patients without measurable scapular or postural imbalance, or those not completing the training, may see limited additional benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center randomized trial compares standard lymphedema care alone to standard care plus scapulothoracic stabilization and postural training in women with secondary upper-extremity lymphedema after breast cancer surgery. Outcomes measured include scapular muscle strength, posture, upper-extremity function, limb volume, and neck awareness at baseline, after treatment, and at 2-month follow-up. The goal is to see if the added stabilization and posture training improve functional recovery beyond conventional therapy. The study addresses a common complication after breast cancer treatment and explores neuromuscular approaches to improve outcomes. Results may inform whether incorporating targeted stabilization and postural exercises enhances standard lymphedema rehabilitation.

Why it matters

Potential benefit: If successful, patients may experience greater shoulder stability, better function, and improved quality of life.

How similar studies have gone: Randomized trials in related lymphedema rehabilitation have shown promise for neuromuscular and postural interventions, but evidence specific to scapulothoracic stabilization in this setting is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female patients aged 18 to 65 years.
* Diagnosed with secondary upper extremity lymphedema following breast cancer surgery (mastectomy).
* Willing to participate in the study.
* Able to provide written informed consent.

Exclusion Criteria:

* Active infection (e.g., cellulitis or lymphangitis).
* Advanced shoulder or cervical pathology.
* Neurological disorders affecting upper extremity function.
* Metastatic disease.
* Receiving active chemotherapy.
* Participation in another intensive lymphedema rehabilitation program within the previous 3 months.

Where it's running

  • Adana Şehir Eğitim ve Araştırma Hastanesi
    Adana, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.